Dual targeting of FGFR3 and ERBB3 enhances the efficacy of FGFR inhibitors in FGFR3 fusion-driven bladder cancer

Phase 1 dose escalation study of seribantumab (MM-121), an anti-HER3 monoclonal antibody, in patients with advanced solid tumors

(2021) Crystal S. Denlinger et al.   INVESTIGATIONAL NEW DRUGS

Futibatinib, an irreversible FGFR1-4 inhibitor, in patients with advanced solid tumors harboring FGF/FGFR aberrations: a phase I dose-expansion study

(2021) Funda Meric-Bernstam et al.   Cancer Discovery

Futibatinib is a novel irreversible FGFR 1-4 inhibitor that shows selective antitumor activity against FGFR-deregulated tumors

(2020) Hiroshi Sootome et al.   CANCER RESEARCH

Fibroblast growth factor receptors in cancer: genetic alterations, diagnostics, therapeutic targets and mechanisms of resistance

(2020) Melanie A. Krook et al.   BRITISH JOURNAL OF CANCER

Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma

(2019) Yohann Loriot et al.   NEW ENGLAND JOURNAL OF MEDICINE

Epidermal Growth Factor Receptor Family and its Role in Gastric Cancer

(2019) Chiara Arienti et al.   Frontiers in Oncology

Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1–3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with FGFR3 Alterations

(2018) Sumanta K. Pal et al.   Cancer Discovery

Comprehensive Genomic Characterization of Upper Tract Urothelial Carcinoma

(2017) Tyler J. Moss et al.   EUROPEAN UROLOGY

Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study

(2017) Lucia Nogova et al.   JOURNAL OF CLINICAL ONCOLOGY

Oncogenic Characterization and Pharmacologic Sensitivity of Activating Fibroblast Growth Factor Receptor (FGFR) Genetic Alterations to the Selective FGFR Inhibitor Erdafitinib

(2017) Jayaprakash D. Karkera et al.   MOLECULAR CANCER THERAPEUTICS

Akt Activation Mediates Acquired Resistance to Fibroblast Growth Factor Receptor Inhibitor BGJ398

(2017) Jharna Datta et al.   MOLECULAR CANCER THERAPEUTICS

Global cancer statistics, 2012

(2015) Lindsey A. Torre et al.   CA-A CANCER JOURNAL FOR CLINICIANS

First-Line Treatment and Prognostic Factors of Metastatic Bladder Cancer for Platinum-Eligible Patients

(2015) Wassim Abida et al.   HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA

Epithelial–mesenchymal transition confers resistance to selective FGFR inhibitors in SNU-16 gastric cancer cells

(2014) Paulina Grygielewicz et al.   Gastric Cancer

FGFR3 Translocations in Bladder Cancer: Differential Sensitivity to HSP90 Inhibition Based on Drug Metabolism

(2014) Jaime Acquaviva et al.   MOLECULAR CANCER RESEARCH

Ligand-associated ERBB2/3 activation confers acquired resistance to FGFR inhibition in FGFR3-dependent cancer cells

(2014) J Wang et al.   ONCOGENE

FGFR3 expression in primary and metastatic urothelial carcinoma of the bladder

(2014) Elizabeth A. Guancial et al.   Cancer Medicine

Identification of Targetable FGFR Gene Fusions in Diverse Cancers

(2013) Yi-Mi Wu et al.   Cancer Discovery

Parallel RNA Interference Screens Identify EGFR Activation as an Escape Mechanism in FGFR3-Mutant Cancer

(2013) M. T. Herrera-Abreu et al.   Cancer Discovery

Molecular Pathways: Fibroblast Growth Factor Signaling: A New Therapeutic Opportunity in Cancer

(2012) A. N. Brooks et al.   CLINICAL CANCER RESEARCH

Oncogenic FGFR3 gene fusions in bladder cancer

(2012) Sarah V. Williams et al.   HUMAN MOLECULAR GENETICS

Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR

(2012) Anirudh Prahallad et al.   NATURE

Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers

(2012) R. Katayama et al.   Science Translational Medicine

EGFR-Mediated Reactivation of MAPK Signaling Contributes to Insensitivity of BRAF -Mutant Colorectal Cancers to RAF Inhibition with Vemurafenib

(2012) Ryan B. Corcoran et al.   Cancer Discovery

FGFR Genetic Alterations Predict for Sensitivity to NVP-BGJ398, a Selective Pan-FGFR Inhibitor

(2012) V. Guagnano et al.   Cancer Discovery

Somatic mutation of fibroblast growth factor receptor-3 (FGFR3) defines a distinct morphological subtype of high-grade urothelial carcinoma

(2011) Hikmat A Al-Ahmadie et al.   JOURNAL OF PATHOLOGY

Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo

(2010) F R Lamont et al.   BRITISH JOURNAL OF CANCER

AZD8931, an Equipotent, Reversible Inhibitor of Signaling by Epidermal Growth Factor Receptor, ERBB2 (HER2), and ERBB3: A Unique Agent for Simultaneous ERBB Receptor Blockade in Cancer

(2010) D. M. Hickinson et al.   CLINICAL CANCER RESEARCH

Mutant fibroblast growth factor receptor 3 induces intracellular signaling and cellular transformation in a cell type- and mutation-specific manner

(2009) E di Martino et al.   ONCOGENE

FGFR2-Amplified Gastric Cancer Cell Lines Require FGFR2 and Erbb3 Signaling for Growth and Survival

(2008) K. Kunii et al.   CANCER RESEARCH